Bardoxolone methyl prevents obesity and hypothalamic dysfunction.

Area of Science:

• Neuroendocrinology
• Obesity Research
• Pharmacology

Background:

• High-fat (HF) diet-induced obesity is linked to hypothalamic leptin resistance and chronic inflammation, impairing energy balance regulation.
• Leptin signaling in the hypothalamus, particularly in the mediobasal and paraventricular nuclei, is crucial for controlling energy homeostasis.
• Bardoxolone methyl (BM), an oleanolic acid derivative, exhibits anti-inflammatory properties.

Purpose of the Study:

• To investigate if bardoxolone methyl (BM) can prevent obesity, hypothalamic leptin resistance, and inflammation in mice fed a high-fat diet.
• To assess the impact of BM on body weight, energy intake, leptin levels, and fat accumulation.
• To evaluate BM's effects on hypothalamic leptin signaling pathways and inflammatory markers.

Main Methods:

• Mice were fed a high-fat diet for 21 weeks with daily oral administration of bardoxolone methyl (BM) at 10 mg/kg.
• Evaluated effects on body weight, energy intake, serum leptin, and peripheral fat.
• Assessed leptin's anorexigenic effects and measured downstream signaling (Akt pathway) and inflammatory cytokines (TNFα, IL-6) in hypothalamic nuclei.

Main Results:

• BM treatment significantly prevented increases in body weight, energy intake, hyperleptinemia, and fat accumulation in HF diet-fed mice.
• BM administration reversed HF diet-induced leptin resistance, restoring leptin's anorexigenic efficacy.
• BM prevented impairments in the hypothalamic Akt signaling pathway and reduced elevated levels of TNFα and IL-6.

Conclusions:

• Bardoxolone methyl (BM) effectively prevents high-fat diet-induced obesity and associated hypothalamic leptin resistance and inflammation in mice.
• BM normalizes hypothalamic leptin signaling and reduces key inflammatory cytokines in the hypothalamus.
• BM represents a potential novel neuropharmacological agent for managing obesity and related metabolic disorders.